The global vaccines market size is calculated at USD 91.97 billion in 2025 and is forecasted to reach around USD 161.4 billion by 2034, accelerating at a CAGR of 6.45% from 2025 to 2034. The North America vaccines market size surpassed USD 37.13 billion in 2024 and is expanding at a CAGR of 6.50% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Vaccines Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Vaccines Market Revenue and Volume, by Type
8.1.1. Recombinant/conjugate/Subunit
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Inactivated
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Live Attenuated
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Viral Vector
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. mRNA
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Toxoid
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Others
8.1.7.1. Market Revenue and Volume Forecast
9.1. Vaccines Market Revenue and Volume, by Route of Administration
9.1.1. Parenteral
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Oral
9.1.2.1. Market Revenue and Volume Forecast
10.1. Vaccines Market Revenue and Volume, by Disease Indication
10.1.1. Viral Diseases
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Bacterial Diseases
10.1.2.1. Market Revenue and Volume Forecast
11.1. Vaccines Market Revenue and Volume, by Age Group
11.1.1. Pediatric
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Adults
11.1.2.1. Market Revenue and Volume Forecast
12.1. Vaccines Market Revenue and Volume, by Distribution Channel
12.1.1. Hospital & Retail Pharmacies
12.1.1.1. Market Revenue and Volume Forecast
12.1.2. Government Suppliers
12.1.2.1. Market Revenue and Volume Forecast
12.1.3. Others
12.1.3.1. Market Revenue and Volume Forecast
13.1. North America
13.1.1. Market Revenue and Volume Forecast, by Type
13.1.2. Market Revenue and Volume Forecast, by Route of Administration
13.1.3. Market Revenue and Volume Forecast, by Disease Indication
13.1.4. Market Revenue and Volume Forecast, by Age Group
13.1.5. Market Revenue and Volume Forecast, by Distribution Channel
13.1.6. U.S.
13.1.6.1. Market Revenue and Volume Forecast, by Type
13.1.6.2. Market Revenue and Volume Forecast, by Route of Administration
13.1.6.3. Market Revenue and Volume Forecast, by Disease Indication
13.1.6.4. Market Revenue and Volume Forecast, by Age Group
13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Volume Forecast, by Type
13.1.7.2. Market Revenue and Volume Forecast, by Route of Administration
13.1.7.3. Market Revenue and Volume Forecast, by Disease Indication
13.1.7.4. Market Revenue and Volume Forecast, by Age Group
13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel
13.2. Europe
13.2.1. Market Revenue and Volume Forecast, by Type
13.2.2. Market Revenue and Volume Forecast, by Route of Administration
13.2.3. Market Revenue and Volume Forecast, by Disease Indication
13.2.4. Market Revenue and Volume Forecast, by Age Group
13.2.5. Market Revenue and Volume Forecast, by Distribution Channel
13.2.6. UK
13.2.6.1. Market Revenue and Volume Forecast, by Type
13.2.6.2. Market Revenue and Volume Forecast, by Route of Administration
13.2.6.3. Market Revenue and Volume Forecast, by Disease Indication
13.2.7. Market Revenue and Volume Forecast, by Age Group
13.2.8. Market Revenue and Volume Forecast, by Distribution Channel
13.2.9. Germany
13.2.9.1. Market Revenue and Volume Forecast, by Type
13.2.9.2. Market Revenue and Volume Forecast, by Route of Administration
13.2.9.3. Market Revenue and Volume Forecast, by Disease Indication
13.2.10. Market Revenue and Volume Forecast, by Age Group
13.2.11. Market Revenue and Volume Forecast, by Distribution Channel
13.2.12. France
13.2.12.1. Market Revenue and Volume Forecast, by Type
13.2.12.2. Market Revenue and Volume Forecast, by Route of Administration
13.2.12.3. Market Revenue and Volume Forecast, by Disease Indication
13.2.12.4. Market Revenue and Volume Forecast, by Age Group
13.2.13. Market Revenue and Volume Forecast, by Distribution Channel
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Volume Forecast, by Type
13.2.14.2. Market Revenue and Volume Forecast, by Route of Administration
13.2.14.3. Market Revenue and Volume Forecast, by Disease Indication
13.2.14.4. Market Revenue and Volume Forecast, by Age Group
13.2.15. Market Revenue and Volume Forecast, by Distribution Channel
13.3. APAC
13.3.1. Market Revenue and Volume Forecast, by Type
13.3.2. Market Revenue and Volume Forecast, by Route of Administration
13.3.3. Market Revenue and Volume Forecast, by Disease Indication
13.3.4. Market Revenue and Volume Forecast, by Age Group
13.3.5. Market Revenue and Volume Forecast, by Distribution Channel
13.3.6. India
13.3.6.1. Market Revenue and Volume Forecast, by Type
13.3.6.2. Market Revenue and Volume Forecast, by Route of Administration
13.3.6.3. Market Revenue and Volume Forecast, by Disease Indication
13.3.6.4. Market Revenue and Volume Forecast, by Age Group
13.3.7. Market Revenue and Volume Forecast, by Distribution Channel
13.3.8. China
13.3.8.1. Market Revenue and Volume Forecast, by Type
13.3.8.2. Market Revenue and Volume Forecast, by Route of Administration
13.3.8.3. Market Revenue and Volume Forecast, by Disease Indication
13.3.8.4. Market Revenue and Volume Forecast, by Age Group
13.3.9. Market Revenue and Volume Forecast, by Distribution Channel
13.3.10. Japan
13.3.10.1. Market Revenue and Volume Forecast, by Type
13.3.10.2. Market Revenue and Volume Forecast, by Route of Administration
13.3.10.3. Market Revenue and Volume Forecast, by Disease Indication
13.3.10.4. Market Revenue and Volume Forecast, by Age Group
13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Volume Forecast, by Type
13.3.11.2. Market Revenue and Volume Forecast, by Route of Administration
13.3.11.3. Market Revenue and Volume Forecast, by Disease Indication
13.3.11.4. Market Revenue and Volume Forecast, by Age Group
13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel
13.4. MEA
13.4.1. Market Revenue and Volume Forecast, by Type
13.4.2. Market Revenue and Volume Forecast, by Route of Administration
13.4.3. Market Revenue and Volume Forecast, by Disease Indication
13.4.4. Market Revenue and Volume Forecast, by Age Group
13.4.5. Market Revenue and Volume Forecast, by Distribution Channel
13.4.6. GCC
13.4.6.1. Market Revenue and Volume Forecast, by Type
13.4.6.2. Market Revenue and Volume Forecast, by Route of Administration
13.4.6.3. Market Revenue and Volume Forecast, by Disease Indication
13.4.6.4. Market Revenue and Volume Forecast, by Age Group
13.4.7. Market Revenue and Volume Forecast, by Distribution Channel
13.4.8. North Africa
13.4.8.1. Market Revenue and Volume Forecast, by Type
13.4.8.2. Market Revenue and Volume Forecast, by Route of Administration
13.4.8.3. Market Revenue and Volume Forecast, by Disease Indication
13.4.8.4. Market Revenue and Volume Forecast, by Age Group
13.4.9. Market Revenue and Volume Forecast, by Distribution Channel
13.4.10. South Africa
13.4.10.1. Market Revenue and Volume Forecast, by Type
13.4.10.2. Market Revenue and Volume Forecast, by Route of Administration
13.4.10.3. Market Revenue and Volume Forecast, by Disease Indication
13.4.10.4. Market Revenue and Volume Forecast, by Age Group
13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Volume Forecast, by Type
13.4.11.2. Market Revenue and Volume Forecast, by Route of Administration
13.4.11.3. Market Revenue and Volume Forecast, by Disease Indication
13.4.11.4. Market Revenue and Volume Forecast, by Age Group
13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel
13.5. Latin America
13.5.1. Market Revenue and Volume Forecast, by Type
13.5.2. Market Revenue and Volume Forecast, by Route of Administration
13.5.3. Market Revenue and Volume Forecast, by Disease Indication
13.5.4. Market Revenue and Volume Forecast, by Age Group
13.5.5. Market Revenue and Volume Forecast, by Distribution Channel
13.5.6. Brazil
13.5.6.1. Market Revenue and Volume Forecast, by Type
13.5.6.2. Market Revenue and Volume Forecast, by Route of Administration
13.5.6.3. Market Revenue and Volume Forecast, by Disease Indication
13.5.6.4. Market Revenue and Volume Forecast, by Age Group
13.5.7. Market Revenue and Volume Forecast, by Distribution Channel
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Volume Forecast, by Type
13.5.8.2. Market Revenue and Volume Forecast, by Route of Administration
13.5.8.3. Market Revenue and Volume Forecast, by Disease Indication
13.5.8.4. Market Revenue and Volume Forecast, by Age Group
13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel
14.1. GSK plc
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Merck & Co Inc
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Pfizer Inc
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Sanofi
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. CSL (Australia), Emergent
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Johnson and Johnson Services, Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Astrazeneca
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Serum Institute of India Pvt Ltd
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Bavarian Nordic
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Mitsubishi Tanabe Pharma Corporation
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client